Trials / Unknown
UnknownNCT05325801
A Study of CAR-T Cells Targeting Both BCMA and GPRC5D in Treatment of Relapsed or Refractory Multiple Myeloma
An Open-Label, Dose Finding Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of BMCA and GPRC5D Dual Target CAR-T Cells Therapy in Patients With Relapsed or Refractory Multiple Myeloma
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 9 (estimated)
- Sponsor
- Zhejiang University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
An Open-Label, Dose Finding Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of BMCA and GPRC5D dual target CAR-T cells therapy in Patients with relapsed or refractory multiple myeloma
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | BMCA and GPRC5D dual target CAR-T cells(OriC321) | Patients will receive lymphodepleting chemotherapy followed by a single infusion of OriC321 |
Timeline
- Start date
- 2022-04-01
- Primary completion
- 2024-03-01
- Completion
- 2025-03-01
- First posted
- 2022-04-13
- Last updated
- 2022-04-13
Source: ClinicalTrials.gov record NCT05325801. Inclusion in this directory is not an endorsement.